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It is well-established that the diagnosis and treatment of breast
cancer are stressful experiences that may be associated with high
levels of psychiatric and psychosocial morbidity during the first
year following diagnosis (Maguire et al, 1978). Although adapta-
tion and quality of life can be enhanced by giving patients infor-
mation appropriately and by involving them in decision-making to
the extent they wish (Fallowfield, 1997), there is clearly a need for
simple, easily administered interventions to help women to cope
with the diagnosis and treatment of breast cancer (Walker and
Eremin, 1996).
There is substantial evidence that quality of life is an indepen-
dent prognostic factor for survival in various types of cancer
(Weeks, 1992; Ratcliffe et al, 1995; Coates et al, 1997). Moreover,
various aspects of quality of life may independently predict
response to chemotherapy. For example, in patients with advanced
breast cancer who underwent chemotherapy, Fraser et al (1993)
found that quality of life at trial entry predicted response to
chemotherapy and, subsequently, survival. However, it is not
known if psychological interventions designed to improve quality
of life can enhance response to adjuvant or neoadjuvant
chemotherapy for breast cancer.
The most convincing evidence for the importance of psycho-
social factors in modulating tumour biology comes from
psychosocial intervention studies. Spiegel et al (1989) found a
doubling in mean (although not median) survival in women with
metastatic breast cancer randomized to a group intervention.
Beneficial effects of psychological interventions on survival have
also been demonstrated in patients with malignant melanoma
(Fawzy et al, 1990) and haematological malignancies (Richardson
et al, 1990; Ratcliffe et al, 1995; Walker, 1998, Walker et al, 1998).
There is a need, therefore, to develop and evaluate interventions
that minimize the psychosocial impact of the diagnosis and treat-
ment of cancer and that may enhance clinical and pathological
responses to chemotherapy (Dreher, 1997).
Relaxation therapy is used extensively with patients who have
cancer (Walker, 1992; Downer et al, 1994). In addition to studies
of the effects of relaxation therapy on treatment-induced nausea,
vomiting and related side-effects (Burish et al, 1988), two random-
ized, controlled studies of the psychological effects of relaxation
have been reported in patients with breast cancer. Bridge et al
(1988) evaluated the effects of relaxation with, or without,
‘peaceful’ imagery in 154 women receiving radiotherapy as out-
patients. Compared with the control group, total mood disturbance
was significantly less in the two intervention groups. The combi-
nation of relaxation and peaceful imagery was significantly better
than relaxation on its own. The second randomized study was very
small (Walker, 1992; Gruber et al, 1993). Thirteen patients with
stage 1 breast cancer were randomized to a delayed treatment
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control or to group relaxation training, relaxing imagery and
electromyographic biofeedback. Although immunological and
biochemical changes were observed, a between-group analysis did
not find any significant changes in quality of life or other psycho-
logical measures. Studies with mixed groups of cancer patients
have reported beneficial effects on mood (Burish et al, 1988;
Bindemann et al, 1991; Holland et al, 1991; Baider et al, 1994).
It may be that relaxation therapy enhances ability to cope with
stress. No randomized studies have directly assessed this, although
Burish et al (1988) followed up 50 cancer patients who had been
taught progressive muscular relaxation to reduce chemotherapy
side-effects. They found that 97% of the respondents would
recommend the technique as an effective coping strategy and they
reported using the technique for a variety of specific problems,
including ‘nervousness’, insomnia and pain.
Like relaxation, visualization is a commonly used form of
complementary medicine: Downer et al (1994) found that visual-
ization was the third most common complementary technique used
by an unselected series of 600 patients in the UK. Gruber et al
(1988) studied ten adults with metastatic cancer. Following two
baseline sessions, relaxation and guided imagery training (visual-
izing host defences destroying malignant cells) were carried out.
Audiotapes were also used, as were group sessions and electro-
myographic feedback. Changes in lymphocyte mitogen respon-
siveness, interleukin-2 secretion, natural killer (NK) cell activity
and production of immunoglobulins were documented. However,
the psychobiological effects of guided imagery alone, or in combi-
nation with relaxation therapy, have not been evaluated in a
randomized study (Simonton et al, 1980).
Hypotheses
Compared with controls receiving the same amount of staff
support, patients randomized to relaxation and guided imagery
will have better quality of life and improved coping skills. Their
clinical and pathological responses to chemotherapy will be supe-
rior and the frequency of relaxation practice will be positively
correlated with response to chemotherapy.
METHODS
Inclusion and exclusion criteria and investigations
The inclusion criteria were: newly diagnosed large or locally
advanced breast cancer (T2 > 4 cm, T3, T4 or N2 node status and M0
Table 1 Pre- and post-chemotherapy scores for the control group (C) and the experimental group (E)
Pre-chemotherapy Post-chemotherapy
Repeated measures analysis of variance/covariance
Between groups Time Group and time
interaction
Mean s.d. Mean s.d. F P F P F P
CECS total C 51.50 (9.69) 52.13 (9.63) 2.02 0.16 2.28 0.14 5.24 0.02
E 50.63 (10.52) 47.58 (10.64)
Anger C 16.33 (3.63) 15.88 (3.49) 0.42 0.52 2.53 0.12 0.10 0.75
E 15.98 (4.46) 15.29 (4.23)
Unhappiness C 17.21 (4.34) 18.00 (3.87) 3.09 0.08 0.14 0.71 6.33 0.01
E 16.83 (3.92) 15.77 (4.07)
Anxiety C 18.04 (4.00) 18.04 (3.89) 1.54 0.22 3.67 0.06 3.67 0.06
E 17.81 (3.98) 16.44 (4.23)
EPQ-L C 11.31 (3.91) 11.67 (4.37) 0.54 0.46 0.20 0.65 2.99 0.09
E 11.17 (4.48) 10.56 (4.69)
GQOL C 3.23 (0.66) 2.90 (0.78) 2.81 0.10 2.97 0.09 4.91 0.03
E 3.25 (0.70) 3.29 (0.80)
MRS Relaxation C 71.56 (45.14) 70.19 (41.30) 3.61 0.06 3.74 0.004 3.06 0.01
E 57.98 (42.98) 73.29 (44.77)
Easy-going C 88.15 (44.06) 85.33 (44.07) 5.31 0.02 1.47 0.21 0.80 0.55
E 73.29 (38.49) 100.00 (36.62)
Happiness C 78.56 (36.47) 92.15 (34.01) 2.62 0.11 0.49 0.78 0.82 0.54
E 79.63 (38.90) 94.15 (31.22)
Energy C 70.31 (34.56) 69.81 (34.81) 0.49 0.49 5.88 0.0005 0.50 0.78
E 67.73 (40.30) 77.18 (41.43)
Confusion C 117.56 (39.00) 120.90 (35.68) 0.79 0.38 1.34 0.26 0.96 0.45
E 107.44 (41.26) 112.89 (33.67)
Confidence C 88.48 (44.33) 89.98 (44.17) 0.05 0.83 2.41 0.04 0.32 0.90
E 87.50 (42.63) 91.21 (39.46)
Total C 514.63 (171.15) 528.35 (154.27) 4.82 0.03 1.14 0.34 0.89 0.49
E 473.56 (151.87) 548.79 (149.59)
RSCL Psychological C 12.54 (2.97) 11.50 (2.60) 3.70 0.06 1.48 0.21 0.40 0.85
E 13.33 (4.10) 11.42 (3.03)
Physical C 27.85 (5.56) 30.54 (7.00) 0.01 0.93 10.84 0.0005 0.36 0.87
E 28.40 (5.00) 31.10 (5.74)
HADS Anxiety C 2.73 (0.77) 2.32 (0.72) 0.23 0.64 2.68 0.03 1.48 0.20
(1 + square root) E 2.71 (0.7) 2.25 (0.72)
HADS Depression C 1.79 (0.65) 1.90 (0.73) 0.87 0.35 5.70 0.0005 0.31 0.90
(1 + square root) E 1.76 0.61) 1.86 (0.67)264 LG Walker et al
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(UICC criteria, 1987), ambulatory Karnofsky performance status
80% or above, aged 75 years or less and suitable for primary
chemotherapy. The exclusion criteria were: contraindications to
combination chemotherapy (cyclophosphamide, vincristine,
doxorubicin and prednisolone) and inability to complete quality of
life questionnaires. Ninety-seven consecutive women who met
these criteria were invited to participate and 96 were willing to
give written, informed consent.
All patients underwent bilateral mammography, ultrasound
imaging of the breast lesion, fine needle aspiration cytology and/or
core biopsy of the breast cancer. Staging investigations carried out
were: serum biochemistry, full blood counts and differentials, plain
radiographs of chest, pelvis and lumbar spine, isotope bone scans,
and abdominal ultrasound (if liver function tests were abnormal).
Trial design
The basic trial design, including the scheduling of treatment and
assessments, is shown in Figure 1. Patients were recruited
following the diagnosis and before the start of chemotherapy. They
were randomized to standard care (control group) or to standard
care plus relaxation training and guided imagery (experimental
group). A stratified procedure was used to ensure that there were
equal numbers of patients in the two arms of the trial (96 patients
were randomized in total). Power calculations showed that a
sample size of 96 patients (48 in each group) would have 80%
power to detect an effect size of approximately 0.6 (alpha = 0.05,
two-tailed).
Following randomization, at 21-day intervals, patients received
six cycles of chemotherapy as follows: cyclophosphamide 1 gm–2
(maximum dose per cycle: 1.8 g); vincristine 1.5 mg m–2
(maximum dose per cycle: 2 mg); doxorubicin 50 mg m–2
(maximum dose per cycle: 90 mg), all given as intravenous bolus
injections and followed by prednisolone 40 mg orally for 5 days.
The dose and timing of chemotherapy was adjusted according to
blood white cell count and platelet count.
Setting
Chemotherapy, relaxation therapy and guided imagery were
administered in the Behavioural Oncology Unit, Aberdeen Royal
Infirmary, UK. Chemotherapy waiting times were minimized and
chemotherapy was normally administered by the same physician.
In addition to scheduled appointments for chemotherapy and blood
samples, patients were welcome to come to the Unit or to tele-
phone at any time. Staff actively elicited concerns and, if possible,
facilitated their resolution. Although we did not arrange formal
group meetings, many patients arranged to meet their peers in the
Unit to discuss issues of common interest with each other and with
the staff. Family members and friends were also made welcome.
An informal, but professional, atmosphere was cultivated and we
tried to help the women to feel it was ‘their’ Unit.
Interventions
Patients were taught progressive muscular relaxation and cue-
controlled relaxation (Hutchings et al, 1980). Before the first cycle
of chemotherapy, patients were issued with audio-cassette record-
ings containing instructions for relaxation training and they were
given a portfolio of ten coloured cartoons to help them visualize
their host defences destroying the cancer cells. They were asked to
practise at least daily and to keep a daily relaxation diary that
contained details of practise frequency, difficulties encountered
and a rating of imagery vividness (0–10 scale). The diaries
permitted evaluation of the relationship between practise
frequency, imagery vividness and response to chemotherapy. In
addition, the first 40 women in the experimental group received
five live training sessions during the 18 weeks of chemotherapy
Assessment of clinical and pathological response to
chemotherapy
Before each cycle of chemotherapy, and prior to surgery, clinical
measurements of the tumour using calibrated skin callipers (four
diameters, at 45-degree intervals) (Cheung and Johnston, 1991)
were recorded. The measurement before surgery was used in the
analysis except in the three patients who died. Response rates were
classified, using standard UICC criteria (UICC, 1987). Clinical
responses were determined by documenting the product of the two
maximal perpendicular diameters (Miller et al, 1981).
Histological responses of excised breast tissue were assessed by
one consultant breast histopathologist (IM) as previously docu-
mented (Brittenden et al, 1994). Briefly, the response to
chemotherapy is graded according to the residual tumour found
histologically as follows: type I – changes in tumour cells but
tumour nests not destroyed; type II – tumour structure destroyed to
a minor degree; type III – tumour structure destroyed to a
moderate degree; type IV – tumour structure destroyed to a severe
degree; type V – no tumour cells in any of the specimens.
Psychological assessments
Personality and coping
There is evidence that psychosocial interventions can change how
cancer patients cope with stress (Greer et al, 1992; Fawzy et al,
1993). In the present study, coping was assessed using the L-scale
of the Eysenck Personality Questionnaire – Revised (EPQ)
(Eysenck and Eysenck, 1991) and the Courtauld Emotional
Control Scale (CECS) (Watson and Greer, 1983). In a medical
context, the L-scale is thought to measure social conformity, high
levels of which may represent a coping strategy characteristic of
the cancer prone (Type C) personality (Ratcliffe et al, 1995). The
Table 2 Patient characteristics (by group) at trial entry
Control Experimental P-value
Mean age (s.d.) 50.1(11.3) 49.3(10.8) 0.71
Tumour stage (numbers)
T2 14 15 0.47
T3 24 28
T4 95
Tx 1
Clinical nodal status
N0 29 29 0.35
N1 15 18
N2 41
Menopausal status
Premenopausal 27 24 0.68
Post-menopausal 21 24Effects of relaxation and guided imagery265
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CECS measures the extent to which individuals cope with dif ficult
emotions (anxiety, anger and unhappiness) by conscious suppres-
sion, and this is also thought to be a characteristic of the T ype C
personality . To evaluate changes in coping in the two arms, the
EPQ-L and the CECS were administered before the first and sixth
cycles of chemotherapy .
Mood and quality of life
The primary outcome measures were the Rotterdam Symptom
Checklist which yields scores for psychological and physical
symptoms (de Haes et al, 1990) and Global Self-rated Quality of
Life (GQOL) assessed by means of a five-point Likert scale
(ranging from ‘very good’ to ‘very poor ’).
The Mood Rating Scale (MRS) measures six bipolar dimen-
sions of mood using visual analogue scales with verbally defined
anchor points (T able 2). Visual analogue scales have been previ-
ously shown to be a reliable method of assessing mood (Bond and
Lader, 1974). The dimensions are based on the factor analytic
studies underpinning the Profile of Mood States (Lorr and McNair ,
1984); however, the MRS is much briefer and more acceptable to
patients. The MRS is sensitive to changes induced by relaxation
and experimental stress in healthy volunteers (Johnson et al,
1996), by chemoimmunotherapy in patients with colorectal cancer
(Walker et al, 1997a) and by a weekend ‘on-call’ in junior medical
staff (Wesnes et al, 1997).
The MRS and the RSCL were administered on seven occasions,
namely prior to each chemotherapy and three weeks after cycle 6.
The GQOL was administered before cycles 1 and 6 only .
Psychiatric disorder
The Structured Clinical Interview for Diagnosis DSM-IIIR (SCID)
(American Psychiatric Association, 1990) was administered by a
consultant clinical psychologist or senior trainee in psychiatry to
make a psychiatric diagnosis if appropriate at the time of study
entry and at the end of chemotherapy . Clinically significant anxiety
and depression were assessed using the Hospital Anxiety and
Depression Scale (HADS). This scale has been widely used in
cancer studies and has been shown to have satisfactory reliability ,
sensitivity and specificity (Zigmond and Snaith, 1983; Razavi et al,
1990; Hopwood et al, 1991; Ibbotson et al, 1994; Hermann, 1997).
Data analysis and ethics
Data were analysed using SPSS MS for W indows. The conserva-
tive ‘intention-to-treat’ method was used. Patients who died or
who were withdrawn from the study , for whatever reasons, were
included: their last score for each variable was repeated for all
remaining time points. Missing data were minimal. For tests
scheduled for seven administrations, the missing data rate was
2.8% and for tests scheduled for two administrations it was 3.1%.
Distributions were screened and transformed if need be to
approximate normality . To minimize the risk of a Type 1 error,
final scores on the mood and quality of life scales (the two RSCL
scales, the six MRS scales and the single-scale GQOL) following
chemotherapy were entered into a multivariate analysis of covari-
ance (baseline scores as covariates) (MANCOV A): an identical
procedure was carried out for the coping measures (EPQ-L and the
three CECS scales). Because both these multivariate analyses
were significant, experimental and control groups were then
compared using repeated measures analysis of variance
(RMANOVA – for variables assessed at two time points) or
covariance (RMANCOVA – baseline score as covariate, for vari-
ables assessed at seven time points) (Figure 1): W ilks’  lwas used
to evaluate the effect of time and time ´group interactions
(Tabachnik and Fidell, 1996). The Mantel Haenszel c2 test of
linear association was used to compare response to chemotherapy
in the two groups. Alpha was set at 0.05 (two-tailed).
The study was approved by the Joint Ethical Committee of the
Grampian Health Board and the University of Aberdeen.
RESULTS
Patients
The patient details for each group at trial entry are shown in Table
1. The two groups did not differ significantly in terms of age,
menopausal status, clinical nodal status and T stage.
There were 74 invasive ductal carcinomas, seven lobular carci-
nomas and two tubular carcinomas. Ten patients had a complete
pathological response and the tumour type, therefore, could not be
assessed. Histological assessment of the tumour was not possible
in the three patients who died during chemotherapy.
Three patients died, five received fewer than six cycles of
chemotherapy, one patient had more than six cycles and one
patient withdrew from the study. To determine if these ten patients
(deviators) differed from the remaining 86 in terms of baseline
variables, the two groups were compared using c2 tests and t-tests.
The two groups did not differ significantly in terms of clinical
tumour size at diagnosis (t= 0.59, ns) clinical nodal status (c2 =
0.68, ns), ER status (c2 = 3.17, ns), psychological treatment (RT
and GI versus control) (c2 = 0.00, ns), EPQ-L scores (t= 1.89, ns)
HADS anxiety (t= 0.67, ns) and HADS depression scores (t=
1.50, ns). Although the ages of the deviators and non-deviators
were similar (t= 1.66, ns), a higher proportion of post menopausal
women deviated from the protocol (c2 = 4.91, P= 0.03).
Chemotherapy
cycle
123456
Week –1 0 3 6 9 12 15 18
EPQ
CECS
SCID
MRS
RSCL
HADS
GQOL
MRS
RSCL
HADS
MRS
RSCL
HADS
MRS
RSCL
HADS
MRS
RSCL
HADS
MRS
RSCL
HADS
GQOL
EPQ
CECS
MRS
RSCL
HADS
SCID
Figure 1Assessment schedule and trial design
Table 3Hospital Anxiety and Depression Scores before and after six cycles
of chemotherapy
Anxiety Depression
Before (%)After (%) Before (%)After (%)
Normal C 29 (60) 38 (79) 46 (96) 45 (94)
(0–7) E 31 (65) 40 (83) 47 (98) 43 (90)
Borderline C 6 (13) 8 (17) 2 (4) 2 (4)
(8–10) E 10 (21) 5 (10) 1 (2) 5 (10)
Abnormal C 13 (27) 2 (4) 0 (0) 1 (2)
(> 11) E 7 (15) 3 (6) 0 (0) 0 (0)266 LG Walker et al
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Forty-six patients received one or more dose reductions.
However, dose reduction was not associated with clinical response
(c2 = 2.34, ns) or with pathological response (c2 = 0.29, ns). Similar
proportions of patients in the psychological treatment groups (c2 =
0.00, ns) received one or more reduced doses of chemotherapy.
The daily diary recordings made each day indicated the
following compliance: 23% – less than 0.5 times daily; 29% – 0.5
to 0.99 times daily; 25% – 1 to 1.5 times daily, 23% – more than
1.5 times daily.
Clinical and pathological responses
The overall clinical response rate after completion of six cycles
of chemotherapy was 73% (complete response, 19%; partial
response, 54%; stasis, 24%; disease progression, 3%).
After completion of chemotherapy, all patients underwent
surgery (except three patients who died). Twenty-three patients
had breast conservation and 70 patients had a mastectomy (all had
axillary sample or clearance). In 62 of these patients, examination
of the excised breast tissue demonstrated the presence of a residual
macroscopic lesion. However, this did not necessarily contain
tumour cells and in some patients comprised fibrous tissue only.
Histological examination of the breast tissue, using the previously
defined protocol, demonstrated a type V response (complete histo-
logical response with no evidence of residual tumour) in ten
patients, type IV in 13 patients, type III in 25 patients, type II in 25
patients and type I in 20 patients.
The two groups did not differ in terms of clinical or pathological
response to chemotherapy (c2 = 0.94, P= 0.33 and c2 = 2.08,
P= 0.15, respectively). However, within the experimental group,
rating of imagery vividness were positively associated with degree
of clinical response (Kendall’s t= 0.25, P= 0.05).
Psychological and psychiatric aspects
Psychometric scores at trial entry are shown in Table 2.
MANCOVA for the coping measures was significant (Wilks’ lF=
3.91, P= 0.006). Means (s.d.) for the two groups before cycles 1
and 6, and the results of repeated measures analyses, are shown in
Table 2. The intervention reduced emotional suppression as
assessed by the CECS total score (RMANOVA group ´time inter-
action F= 5.24, P= 0.02) and the CECS unhappiness subscale
(RMANOVA group ´time interaction F= 6.33, P= 0.01) (Table
2). When the control group, the group practising less than daily, and
the group practising daily or more were compared, a significant
linear relationship was found for CECS unhappiness (RMANOVA
group ´time interaction F= 3.86, P= 0.03) and CECS total
(RMANOVA group ´time interaction F= 4.75,P= 0.01); women
who practised daily or more had lower scores than control women
for CECS unhappiness (RMANCOVA between group F= 4.13,P=
0.01; group ´time interactionF= 6.75, P= 0.01) and CECS total
(RMANOVA group ´time interaction F= 8.64, P= 0.004). EPQ-L
scores were not significantly different in the experimental and
control groups, although the difference was in the predicted direc-
tion (RMANOVAgroup ´time interaction F= 2.99, P= 0.09).
MANCOVA for the quality of life measures yielded an overall
significant result (Wilks’ lF= 2.18, P= 0.03). Means (s.d.) for
pre-cycle 1 and 3 weeks, post-cycle 6, and the results of repeated
measures analyses, are shown in Table 2 (for GQOL means are for
pre-cycles 1 and 6). During chemotherapy, patients receiving the
psychological intervention had higher GQOL scores than those in
the control group (RMANOVA group ´time interaction F= 4.91,
P= 0.03): moreover, the GQOL scores of patients in the control
group deteriorated significantly during chemotherapy (Student’s
t= 2.96, P= 0.005). However, this was not the case for those in
the experimental group (Student’s t= 0.33, P= 0.74). The psycho-
logical intervention also enhanced scores of MRS relaxation
(RMANOVA between groups F= 3.06, P= 0.01), MRS easy-
goingness (between groups F= 5.31, P= 0.02) and MRS total
scores (between groups F= 4.82, P= 0.03) (Table 2). RSCL
psychological symptom scores were lower in the experimental
group (RMANCOVA between groups F= 3.70, P< 0.06) and this
reaches significance if EPQ N scores are included as a covariate
(RMANCOVA between groups F= 4.04, P< 0.05).
During the study, a number of significant time effects emerged
(Table 2). MRS relaxation and MRS confidence increased after the
first cycle and then decreased following cycle 6 (F= 3.74, P=
0.004 and F= 2.41, P= 0.04, respectively). MRS energy scores,
decreased following cycle 1 and increased following cycle 6 (F=
5.88, P< 0.0005). HADS depression increased steadily until cycle
5 and then declined (F= 4.89, P= 0.001), whereas HADS anxiety
declined sharply in both groups prior to the second cycle of
chemotherapy and remained at a low level (F= 2.66, P= 0.03)
thereafter. RSCL physical symptoms increased markedly
following cycle 1 and, thereafter, remained constant until after
cycle 6 (F= 11.20, P< 0.0005).
Table 3 shows HADS scores categorized as ‘normal’ (0–7),
‘borderline’ (8–10) and ‘abnormal’ (11 and above) for the two
groups during the main phases of the study. The experimental and
control groups did not differ significantly before (anxiety c2 =
1.00, P= 0.32: depression c2 = 0.34, P= 0.56) or after (anxiety
c2 = 0.04, P= 0.85: depression c2 = 0.10, P= 0.75) chemotherapy.
There was a strikingly low level of abnormal scores after
chemotherapy for anxiety (5%) and depression (0%). Using a cut-
off score of 18 for combined scores of anxiety and depression to
identify clinically significant disorder (Hopwood et al, 1991), 4%
obtained an abnormal score before and 2% after chemotherapy.
The two groups did not differ significantly from each other before
(c2 = 1.04, P= 0.31) or after (c2 = 0.00, P= 1.00) chemotherapy.
Mean HADS scores (transformed 1 + square root) before and after
chemotherapy are shown in Table 2.
At trial entry, only four (4%) patients met the criteria for a SCID
diagnosis (two in the control group and two in the experimental
group). Two patients had major depression, one patient had panic
disorder (without agoraphobia) and one patient (who was on anti-
depressant medication) qualified for a diagnosis of generalized
anxiety disorder and also met the criteria for alcohol abuse.
At the end of chemotherapy, seven (7%) patients received a
psychiatric diagnosis (two in the control group and five in the
experimental group). Two patients (both in the experimental
group) had been given a diagnosis at trial entry. The patient who
abused alcohol continued to do so, although she no longer met the
criteria for generalized anxiety disorder and she had discontinued
antidepressant medication. The second patient who had had major
depression now met the criteria for adjustment disorder (depressed
type). Of the five new cases, three had major depression (two of
whom had a history of major depression) and two had an adjust-
ment disorder (one depressed type and one anxiety type).
DISCUSSION
Women in both arms of the study showed a high level of enthu-
siasm and commitment to the project. Compliance with relaxationEffects of relaxation and guided imagery 267
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and imagery was good: 77% of the women practised at least once
every second day, and 48% at least daily, during the 18 weeks
when they were receiving chemotherapy.
Between-group analysis, using the conservative intention-to-
treat method, showed that the intervention had beneficial psycho-
logical effects: women in the experimental group were more
relaxed and easy going (MRS), they had fewer psychological
symptoms (RSCL) and they had higher self-rated quality of life
(GQOL) during chemotherapy. Because there were so few missing
data, an analysis including only those with complete data yielded
similar results. This is the first demonstration that relaxation and
guided imagery are beneficial for women receiving primary
chemotherapy, and the results are consistent with previous studies
of relaxation in other groups of cancer patients (Bindemann et al,
1991; Holland et al, 1991; Baider et al, 1994).
The very low level of clinically significant anxiety or depression,
whether assessed by means of the SCID or the HADS, in both
groups after chemotherapy is striking. The most likely reason for
this is the overall milieu provided in the Unit: open access to the
Unit, sensitivity to the needs of the patients for information and
practical advice, involvement in clinical decision-making to the
extent which patients wished, minimization of waiting time for
chemotherapy, and the informal, friendly atmosphere (Paraskevaidis
et al, 1993; Walker and Eremin, 1996; Fallowfield, 1997). An audit
of patient satisfaction at the end of chemotherapy showed that 93%
of patients were ‘satisfied’ or ‘very satisfied’ with the emotional
support they had received from hospital staff. The results make it
clear that a high incidence of clinically significant distress is not
inevitable following the diagnosis of breast cancer and during
primary chemotherapy. Future studies should address the relative
cost-effectiveness of providing a setting such as the above versus a
more specialist service that only deals with problems once they have
assumed ‘clinical significance.’
Given the low incidence of clinically significant disorder, it is
not surprising that the two groups did not differ either in terms of
the HADS or the SCID. Moreover, because the high level of satis-
faction with emotional support was identical in the two arms (93%
of both groups were ‘satisfied’ or ‘very satisfied’ with the
emotional support received in hospital), this study provides a
rigorous test of the effects of relaxation and guided imagery per se.
The effects of the intervention may have been even more striking
if the control group had had less support.
As predicted, comparison of the two groups indicated that the
intervention had an effect on how patients coped with distress.
Following chemotherapy, women in the intervention group were
less likely to suppress their emotions, particularly unhappiness
(CECS). Moreover, this was most marked in those practising at
least daily. The difference between the two groups for social
conformity (EPQ-L) did not reach statistical significance at the
end of chemotherapy; however, at follow-up 19 weeks later (12
weeks after radiotherapy), women in the experimental group
had significantly lower scores than those in the control group
(P < 0.05). This may be important in the light of our previous
finding in patients with Hodgkin’s or non-Hodgkin’s lymphoma
that L-scores were a significant independent prognostic factor for
5-year survival (Ratcliffe et al, 1995).
We hypothesized that clinical and pathological responses to
chemotherapy would be superior in the experimental group and
that the frequency of relaxation practise would be positively
correlated with response to chemotherapy. The hypothesis was
supported in part. A modest correlation was found between
imagery ratings and clinical response. However, there was no
evidence that women in the experimental group had an improved
clinical or pathological response to chemotherapy.
There were immunological differences between the experi-
mental and control groups. In keeping with the finding of Fawzy et
al (1990) that a psychoeducational intervention altered host
defences in patients with malignant melanoma, relaxation and
guided imagery in this study also had immunological effects,
including enhanced lymphokine-activated killer (LAK) cell cyto-
toxicity, higher numbers (and %) of activated T-cells and reduced
blood levels of tumour necrosis factor a (Walker et al, 1997b). The
intervention, therefore, had a number of biological effects,
although the clinical significance of these is not yet clear.
The study design does not permit assessment of the relative
contributions of relaxation therapy and guided imagery. Future
work is required to clarify this. However, the findings suggest that
the combination should be offered to women with breast cancer
undergoing primary medical therapy for large and locally
advanced breast cancer and this is now routine policy in the Unit.
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